Joseph Batchelor

Head of Structural Biology for US Biologics Research Sanofi

Dr. Joseph Batchelor is Head of Structural Biology for US Large Molecule Research at Sanofi, where he leads efforts to enable structure-guided design across biologics and small molecule programs. Since joining Sanofi in 2013, he has pioneered the integration of cryo-electron microscopy into the company’s discovery workflows, establishing a hybrid internal–external cryo-EM platform that delivers high-resolution structures for challenging targets. Trained as a crystallographer, Joseph transitioned to cryo-EM in 2016 and has since advanced structural biology capabilities to support non-crystallizable systems. He earned his Ph.D. from the University of California, Berkeley, and completed postdoctoral training at Washington University School of Medicine.

Seminars

Thursday 5th February 2026
Panel Discussion: How Do We Push the Boundaries in Structure-Based Drug Design? What’s Next & What’s Needed?
9:00 am

As the toolbox of techniques and modalities continues to expand, structure-based drug design is at a crossroads. This interactive panel invites the audience and expert panellists to reflect on the most pressing challenges, biggest opportunities, and future directions to maximize the impact of structural insights on drug discovery.

Key Discussion Points:

  • What are the key bottlenecks still limiting the impact of SBDD (resolution, dynamics, integration, translation to clinic)?
  • Which emerging tools (AI, cryo-ET, integrative modelling, real-time structural methods) will reshape the field in the next 5 years?
  • How can we bridge the gap between structural data and actionable design decisions for both small molecules and biologics?
  • What collaborations, technologies, or standards are still needed to make SBDD more predictive and accessible?
Wednesday 4th February 2026
Optimizing Large Molecules & Fusion Proteins for Improved Efficacy & Reduced Liabilities with Structural Insight
1:30 pm
  • Leveraging structural insights to engineer large molecules and fusion proteins with enhanced potency and selectivity
  • Applying structure-guided approaches to minimize liabilities such as immunogenicity, instability, or off-target effects
  • Exploring strategies to optimize molecular architecture for improved developability, safety, and therapeutic efficacy
joseph batchelor